MON-179 UTILITY OF CLINDAMYCIN AND PRIMAQUINE FOR PNEUMOCYSTIS PNEUMONIA IN RENAL TRANSPLANT RECIPIENTS

Abstract

Pneumocystis jirovecii pneumonia (PJP) is a potentially life-threatening infection that occurs in immunocompromised patients. PJP occurs in approximately 5–15% of transplant patients, depending on the transplanted organ and the degree of immunosuppression. In the absence of appropriate treatment, the mortality rate of PJP is 90–100%, and can be as high as 50% despite adequate therapy. Trimethoprim-Sulphamethoxazole (TMP-SMX) is the first choice for the treatment of PJP. Alternative drugs include intravenous Pentamidine, Dapsone, combination of Clindamycin and Primaquine (C+P).